Cardiff Oncology (CRDF) Expected to Announce Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) will likely be announcing its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $0.09 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Cardiff Oncology Stock Down 7.2 %

CRDF stock opened at $4.23 on Wednesday. Cardiff Oncology has a 52-week low of $1.66 and a 52-week high of $6.42. The stock’s fifty day simple moving average is $4.07 and its 200-day simple moving average is $3.20. The stock has a market capitalization of $216.30 million, a price-to-earnings ratio of -4.50 and a beta of 1.77.

Insider Buying and Selling at Cardiff Oncology

In related news, Director Gary W. Pace acquired 350,115 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were bought at an average cost of $2.60 per share, with a total value of $910,299.00. Following the completion of the transaction, the director now directly owns 1,047,876 shares of the company’s stock, valued at $2,724,477.60. This trade represents a 50.18 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

CRDF has been the topic of several analyst reports. Piper Sandler raised their price objective on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. HC Wainwright reduced their target price on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, November 8th.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.